Literature DB >> 20948919

Prognostic role of Rb, p16, Cyclin D1 proteins in soft tissue sarcomas.

Byoung Yong Shim1, Jinyoung Yoo, Yeon-Soo Lee, Young Sun Hong, Hoon-Kyo Kim, Jin-Hyoung Kang.   

Abstract

PURPOSE: The aim of this study was to determine the expressions of Rb, p16, and cyclin D1 in soft tissue sarcomas, and we also wanted to identify the prognostic factors according to the clinicalpathologic features.
MATERIALS AND METHODS: We reviewed the charts and radiographic films of 66 sarcoma patients. Tissue samples were collected from these patients. Immunochemistry was performed using formalin-fixed, paraffin-embedded tissue samples to examine the expressions of p16, Rb, and cyclin D1 proteins.
RESULTS: The median duration of overall survival was 47.8 months (range, 20.0 to 70.7 months) and the 5 years survival rate was 39%. As for the correlation between the degree of immunohistochemical staining for Rb protein and the histological tumor grades, there was a significant difference with a p-value of 0.019. However, no significant correlation was shown for p16 and cyclin D1. The overall survival duration of the Rb negative group (staining cell <20%) and the heterogeneous group (cell staining 20 to 80%) was 53.5±6.6 months and the overall survival duration of the Rb homogeneous group was 18.3±6.4 months, and there was a significant difference with a p-value of 0.016. However, no significant difference was shown between the survival rate according to the p16 and cyclin D1 expressions. On the multivariate analysis that was done with Rb, p16, the tumor size, grade and site, and patient age, the Rb gene expression was the most significant independent prognostic factor with a risk ratio of 3.01 (p=0.04).
CONCLUSION: The expression of Rb protein was correlated with the histologic grade and overall survival of patients with soft tissue sarcomas.

Entities:  

Keywords:  Cyclin D1; Retinoblastoma protein; Sarcoma; p16 protein

Year:  2010        PMID: 20948919      PMCID: PMC2953777          DOI: 10.4143/crt.2010.42.3.144

Source DB:  PubMed          Journal:  Cancer Res Treat        ISSN: 1598-2998            Impact factor:   4.679


  16 in total

1.  No p16INK4A/CDKN2/MTS1 mutations independent of p53 status in soft tissue sarcomas.

Authors:  A Meye; P Würl; R Hinze; D Berger; M Bache; H Schmidt; F W Rath; H Taubert
Journal:  J Pathol       Date:  1998-01       Impact factor: 7.996

2.  Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin-dependent kinase 4 in human primary soft-tissue sarcoma.

Authors:  J Yao; R E Pollock; A Lang; M Tan; P W Pisters; D Goodrich; A El-Naggar; D Yu
Journal:  Clin Cancer Res       Date:  1998-04       Impact factor: 12.531

3.  Prognostic role of cyclin D1 in retroperitoneal sarcomas.

Authors:  S H Kim; N H Cho; G Tallini; M Dudas; J J Lewis; C Cordon-Cardo
Journal:  Cancer       Date:  2001-01-15       Impact factor: 6.860

4.  Loss of RB and MTS1/CDKN2 (p16) expression in human sarcomas.

Authors:  J A Cohen; J Geradts
Journal:  Hum Pathol       Date:  1997-08       Impact factor: 3.466

5.  Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas.

Authors:  S H Kim; J J Lewis; M F Brennan; J M Woodruff; M Dudas; C Cordon-Cardo
Journal:  Clin Cancer Res       Date:  1998-10       Impact factor: 12.531

6.  Altered p16/MTS1/CDKN2 and cyclin D1/PRAD-1 gene expression is associated with the prognosis of squamous cell carcinoma of the esophagus.

Authors:  H Takeuchi; S Ozawa; N Ando; C H Shih; K Koyanagi; M Ueda; M Kitajima
Journal:  Clin Cancer Res       Date:  1997-12       Impact factor: 12.531

7.  Reproducibility of a histopathologic grading system for adult soft tissue sarcoma.

Authors:  J M Coindre; M Trojani; G Contesso; M David; J Rouesse; N B Bui; A Bodaert; I De Mascarel; A De Mascarel; J F Goussot
Journal:  Cancer       Date:  1986-07-15       Impact factor: 6.860

8.  Predictive value of expression of p16INK4A, retinoblastoma and p53 proteins for the prognosis of non-small-cell lung cancers.

Authors:  F Hommura; H Dosaka-Akita; I Kinoshita; T Mishina; H Hiroumi; S Ogura; H Katoh; Y Kawakami
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

9.  p16 protein expression is associated with a poor prognosis in squamous cell carcinoma of the lung.

Authors:  C I Huang; T Taki; M Higashiyama; N Kohno; M Miyake
Journal:  Br J Cancer       Date:  2000-01       Impact factor: 7.640

10.  Altered patterns of retinoblastoma gene product expression in adult soft-tissue sarcomas.

Authors:  M S Karpeh; M F Brennan; W G Cance; J M Woodruff; D Pollack; E S Casper; M E Dudas; E Latres; M Drobnjak; C Cordon-Cardo
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

View more
  6 in total

1.  High p16 Expression Is Associated with Malignancy and Shorter Disease-Free Survival Time in Solitary Fibrous Tumor/Hemangiopericytoma.

Authors:  Yuanxin Liang; Robert S Heller; Julian K Wu; Carl B Heilman; Arthur S Tischler; Knarik Arkun
Journal:  J Neurol Surg B Skull Base       Date:  2018-08-21

2.  Sarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?

Authors:  Elisabetta Pennacchioli; Giulio Tosti; Massimo Barberis; Tommaso M De Pas; Francesco Verrecchia; Claudia Menicanti; Alessandro Testori; Giovanni Mazzarol
Journal:  Clin Exp Metastasis       Date:  2012-06-15       Impact factor: 5.150

3.  GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas.

Authors:  Toshiaki Haraguchi; Hiroaki Miyoshi; Koji Hiraoka; Shintaro Yokoyama; Yukinao Ishibashi; Toshihiro Hashiguchi; Koutaro Matsuda; Tetsuya Hamada; Takahiro Okawa; Naoto Shiba; Koichi Ohshima
Journal:  PLoS One       Date:  2016-06-01       Impact factor: 3.240

4.  Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

Review 5.  The role of molecular pathology in mediastinal sarcomas.

Authors:  David Ilan Suster
Journal:  Mediastinum       Date:  2020-12-30

6.  Carcinosarcoma, a Rare Malignant Neoplasm of the Pancreas.

Authors:  Jaffar Khan; Liang Cheng; Michael G House; Shunhua Guo
Journal:  Curr Oncol       Date:  2021-12-12       Impact factor: 3.677

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.